C5 and paroxysmal nocturnal hemoglobinuria: The company model was constructed in MS Excel and was used to compare the cost effectiveness of pegcetacoplan versus eculizumab and pegcetacoplan versus ravulizumab in patients with PNH who had baseline Hb levels < 10.5 g/dL despite treatment with a stable dose of a C5 inhibitor for ≥ 3 months.